Deepening responses associated with improved progression-free survival with ixazomib versus placebo as posttransplant maintenance in multiple myeloma

In the TOURMALINE-MM3 study, post-autologous stem cell transplantation maintenance therapy with the oral proteasome inhibitor ixazomib versus placebo significantly improved progression-free survival (PFS), with a favorable safety profile. With ixazomib versus placebo maintenance, deepening responses...

Descripción completa

Detalles Bibliográficos
Autores principales: Goldschmidt, Hartmut, Dimopoulos, Meletios A., Rajkumar, S. Vincent, Weisel, Katja C., Moreau, Philippe, Chng, Wee-Joo, Mikala, Gábor, Cavo, Michele, Ramasamy, Karthik, Suryanarayan, Kaveri, Teng, Zhaoyang, Labotka, Richard, Mateos, Maria Victoria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7584475/
https://www.ncbi.nlm.nih.gov/pubmed/32327729
http://dx.doi.org/10.1038/s41375-020-0819-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7584475/
https://www.ncbi.nlm.nih.gov/pubmed/32327729
http://dx.doi.org/10.1038/s41375-020-0819-8

Ejemplares similares